Optimizing antiplatelet and anticoagulant agents in the perioperative orthopedic surgery patient

Orthopedics

Volumn 28, Issue 5, 2005, Pages 453-458

  Oh, Jennifer J ^a   Robon, Matthew J ^b   Akers, Wendell S ^a  

^a University of Kentucky   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; DESULFATOHIRUDIN; DIGOXIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LY 517717; OMEPRAZOLE; PIROXICAM; PROTAMINE; RAZAXABAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN INHIBITOR; TICLOPIDINE; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TENDENCY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GRAFT OCCLUSION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PATIENT CARE; PERIOPERATIVE PERIOD; PLACENTA; POSTOPERATIVE THROMBOSIS; PROCESS OPTIMIZATION; SURGICAL PATIENT;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDIC PROCEDURES; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES;

EID: 20344367540     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Haines ST, Racine E, Zeolla M. Venous thromboembolism. In: DiPiro JT, Talbert RL, ed. Pharmacotherapy: A Pathophysiologic Approach. McGraw-Hill Companies, 2002:337-373.
2. Andersen JC. Advances in anti-coagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Semin Thromb Hemost. 2004; 30:609-618.
3. Michota F. Venous thromboembolism: who is at risk and who is being treated. JCP. 2004; 2:5-10.
4. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Chest. 2004; 126:338S-400S.
5. Ollendor DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health-Syst Pharm. 2002; 59:1750-1754.
6. Patrono C, Colter B, Fitzgerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2004; 126(3):234S-264S.
7. Klasco RK, ed. DRUGDEX System. Greenwood Village, Colo: Thomson MICROMEDEX; Edition expires 3/2005.
8. Organon Sanofi-Synthelabo LLC Package Insert. Arixtra (fondaparinux sodium injection). West Orange, NJ: Organon Sanofi-Synthelabo LLC; 2003.
9. CenterWatch. Summary: Flexibility in Administration of Arixtra for Prevention of Symptomatic Venous Thromboembolism (VTE) in Orthopedic Surgery. Available at: http://www.centerwatch.com/patient/studies/stu48543.html. Accessed March 17, 2005.
10. Weitz JI, Meddeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematology (Am Soc Hematol Educ Program). 2004; 424-438.
11. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Throm Haemost. 2003; 1:2368-2373.
12. Witter FR, King TM, Blake DA. Adverse effects of cardiovascular drug therapy on the fetus and neonate. Obstet Gynecol. 1981; 58(5 suppl):100S-105S.
13. Aventis Pharmaceuticals Package Insert: Lovenox (enoxaparin sodium injection). Bridgewater, NJ: Aventis Pharmaceuticals; 2004.
14. Hirsh J, Raschke R. Heparin and low- molecular-weight heparin. Chest. 2004; 126:188S-203S.
15. Merli GJ, Weitz HH. Preoperative evaluation for noncardiac surgery. Available at: http://www.patientcareonline.com/patcare/article/ articleDetail.jsp?id=112794. Accessed February 20, 2005.
16. Ansell J, Hirsch J, Potter L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists. Chest. 2004;126:204S-233S.
17. Weitz JI, Hirsch J, Samama MM. New anticoagulant drugs. Chest. 2004; 126:265S-286S.